https://corporatefinanceinstitute.com/resources/knowledge/valuation/dcf-pros-and-cons/
Pros and Cons of DCF Analysis
What are the Pros of DCF analysis?
It would be best for a financial analyst to use the DCF analysis if they are confident about the assumptions being made. A discounted cash flow model requires a lot of detail to make an estimate of the intrinsic value of a stock, and each of those details requires an assumption.
The main Pros of a DCF model are:
Extremely detailed
Includes all major assumptions about the business
Determines the “intrinsic” value of a business
Does not require any comparable companies
Can be performed in Excel
Includes all future expectations about a business
Suitable for analyzing mergers and acquisition
Can be used to calculate the internal rate of return IRR of an investment
Scenarios can be built-in
Allows for sensitivity analysis
What are the Cons of DCF analysis?
Despite the advantages of the DCF analysis, it is also exposed to some disadvantages. The main drawback of DCF analysis is that it’s easily prone to errors, bad assumptions, and overconfidence in knowing what a company is actually “worth”.
The main Cons of a DCF model are:
Requires a large number of assumptions
Prone to errors
Prone to overcomplexity
Very sensitive to changes in assumptions
A high level of detail may result in overconfidence
Looks at company valuation in isolation
Doesn’t look at relative valuations of competitors
Terminal value is hard to estimate and represents a large portion of the total value
Challenging to estimate the Weighted Average Cost of Capital (WACC)
- Forums
- ASX - By Stock
- Todays fair value for SLX
SLX
silex systems limited
Add to My Watchlist
0.46%
!
$4.29

...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.29 |
Change
-0.020(0.46%) |
Mkt cap ! $1.021B |
Open | High | Low | Value | Volume |
$4.33 | $4.43 | $4.23 | $2.214M | 513.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 700 | $4.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.36 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 700 | 4.250 |
1 | 4000 | 4.230 |
1 | 4761 | 4.220 |
1 | 500 | 4.160 |
2 | 13000 | 4.150 |
Price($) | Vol. | No. |
---|---|---|
4.360 | 500 | 1 |
4.380 | 16467 | 1 |
4.390 | 500 | 1 |
4.410 | 2000 | 1 |
4.430 | 3159 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
SLX (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online